Jazz Pharmaceuticals (JAZZ) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Jazz Pharmaceuticals (JAZZ) overview

Jazz Pharmaceuticals (JAZZ) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 4,268m and operating profit of USD -430m; the year-end share price was 170.00 USD and market capitalisation was USD 10,444m. Jazz Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Jazz Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 4,319mFY 2025
Share price170.00 USDFY 2025 year end
RevenueUSD 4,268mFY 2025
Operating profitUSD -430mFY 2025
Net earningsUSD -356mFY 2025
Market capitalisationUSD 10,444mFY 2025 year end

About Jazz Pharmaceuticals

Jazz Pharmaceuticals is a global biopharmaceutical company focused on medicines for rare diseases and patients with limited treatment options. Its portfolio includes therapies for epilepsies, cancers and sleep disorders, including Xywav, Epidiolex, Ziihera, Modeyso, Zepzelca and Rylaze. The company develops therapies through research and development programs and markets approved medicines to patients and healthcare providers in multiple countries.

Generate the Jazz Pharmaceuticals report

Jazz Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Jazz Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Jazz Pharmaceuticals

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.